Monitor upcoming regulatory engagement for Phase 3 adjuvant study design in IR NMIBC and initial BEACH301 safety sentinel cohort results, both expected in 2027. The $400M financing removes near-term dilution risk but increases share count.
Drug in focus
TYRA drug pipeline →dabogratinib
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 2
- Time to market
- Dabogratinib is in Phase 2 development across all three indications. A pivotal Phase 3 study in NMIBC is being planned following the SURF302 data, but no specific start date has been given. The earliest potential approval would likely be several years away, contingent on successful Phase 3 data and FDA review.
- Next catalyst
- None dated
What to watchThe next hard catalyst is the BEACH301 Phase 2 safety sentinel cohort data in pediatric achondroplasia, expected by end of Q1 2027. Positive safety and growth data could re-rate the stock after the September 2026 SURF302 selloff; negative safety signals would damage the achondroplasia thesis. Separately, watch for details on a planned pivotal Phase 3 study in NMIBC, which would be the next major binary event for the bladder cancer program.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 10 $21.00entry
- T+1 · 6d ago −0.14%α −1.46% · $20.97
- T+4 · todayOpen
- T+5 · in 6h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Tyra Biosciences reported Q3 2026 net loss of $51.1M, wider than the $29.9M loss in Q3 2025, driven by increased R&D spending on its dabogratinib clinical programs. The company highlighted initial Phase 2 SURF302 results showing a 79% ORR and 64% CR rate at 60 mg QD in IR NMIBC, and disclosed a $400M September financing that extended cash runway through 2030. No revenue or EPS consensus was provided for the current quarter.
Key Financial Metrics
Key Facts
- Q3 2026 net loss of $51.1M vs $29.9M in Q3 2025
- Cash, cash equivalents and marketable securities of $700.5M as of September 30, 2026
- Completed $400M underwritten public offering in September 2026
- Initial Phase 2 SURF302 results: 79% ORR and 64% CR rate at 60 mg QD in IR NMIBC
- First SURF303 patient achieved CR at 3-month assessment with 60 mg QD
- BEACH301 advanced to sixth dose level; initial results expected in 2027
- R&D expenses $43.1M in Q3 2026 vs $25.5M in Q3 2025
- Cash runway extended through 2030
Financial Impact
Net loss widened to $51.1M from $29.9M YoY; cash balance increased to $700.5M from $383.5M at Q1 2026 after $400M financing
Risk Factors
- Clinical-stage company with no approved products or revenue
- Net loss widening as R&D spending increases across three Phase 2 trials
- Initial SURF302 results are from a small sample (n=14) and may not predict final outcomes
- Dependence on successful regulatory feedback for Phase 3 study design
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-454474 |
| Document: tyra-20261110.htm | 0001193125-26-454474 |
| Document: 0001193125-26-454474-index-headers.html | 0001193125-26-454474 |
| Document: 0001193125-26-454474-index.html | 0001193125-26-454474 |
| Document: 0001193125-26-454474.txt | 0001193125-26-454474 |
| 8-K Data (Synthetic) | 0001193125-26-454474 |
Track record
13 reports on TYRA
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +20.37% at T+60 after the Jun 26, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 10, 20266d ago 8-K Neutral 4/10 Viewing Entry $21.00 Now $19.74 −6.00% settles Nov 17
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $21.75 to $21.53 Now $19.74 −9.24% ▼ −1.03% −0.32% vs SPY
- Sep 21, 20268w ago SC 13G Neutral 4/10 Entry $25.57 to $21.98 Now $19.74 −22.80% ▼ −14.04% −12.85% vs SPY
- Sep 17, 20268w ago Insider Cluster Bullish 8/10 Entry $25.73 to $21.76 Now $19.74 −23.28% ▼ −15.43% −16.70% vs SPY
- Sep 14, 20269w ago S-3ASR Neutral 3/10 Entry $25.07 to $25.65 Now $19.74 −21.26% ▲ +2.31% +2.21% vs SPY
- Sep 9, 20269w ago 8-K Bullish 6/10 Entry $22.01 to $24.35 Now $19.74 −10.31% ▲ +10.63% +11.73% vs SPY
- Aug 4, 202614w ago 424B5 Bearish 6/10 Entry $25.71 to $25.30 Now $19.74 +23.22% ▲ +1.59% +1.95% vs SPY
- Jun 26, 202620w ago 144 Bearish 6/10 Entry $32.11 to $30.86 Now $19.74 +38.52% ▲ +3.89% +5.28% vs SPY
- May 13, 202626w ago 8-K Mixed 5/10 Entry $36.19 to $33.78 Now $19.74 −45.45% ▼ −6.66% −5.50% vs SPY
- Apr 20, 202630w ago 3 Neutral 2/10 Entry $36.69 to $35.06 Now $19.74 −46.20% ▼ −4.44% −5.53% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers